Launch week offerEnds in00h00m00s

annual Promonthly Pro

Antoine Saliba

Mayo Clinic

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (10)

Somedeb Ball

Vanderbilt University Medical Center

UNITED STATES

View details

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rashmi Kanagal Shamanna

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sharad Kumar

Badley Distinguished Professor

University of South Australia

AUSTRALIA

View details

Anmol Baranwal

Assistant Professor

Rush University Medical Center

UNITED STATES

View details

Kelly Lim

University of Adelaide

AUSTRALIA

View details

Christopher Hahn

University of South Australia

AUSTRALIA

View details

Sergei Doulatov

Associate Professor

Columbia University

UNITED STATES

View details

William Hogan

Mayo Clinic Minnesota

UNITED STATES

View details

Hamish Scott

University of South Australia

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Antoine Saliba

Research Interests

Make your next move.

Explore related searches

Articles (20)

Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s)

Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia

Menin Inhibition in Acute Myeloid Leukemia: Rewiring Leukemic Transcriptional Networks

Treatment-specific prognostic performance of ELN 2022, ELN 2024, and Beat AML 2024: a real-world AML validation study

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study

RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm

Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort

Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.

Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.

Clinical characteristics and prognostic significance of co-mutated SETBP1/GATA2 myeloid neoplasms.

Outcomes and mortality risk scoring for infections caused by carbapenem-resistant Escherichia coli and Klebsiella pneumoniae

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy.

Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia

Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.

Collaborators (10)

Somedeb Ball

Hussein A. Abbas

Rashmi Kanagal Shamanna

Sharad Kumar

Anmol Baranwal

Kelly Lim

Christopher Hahn

Sergei Doulatov

William Hogan

Hamish Scott

Make your next move.